Empagliflozin does not Increase the Risk of Fractures in Type 2 Diabetes Patients
As per a recently published study in Diabetes Care, the Empagliflozin therapy does not increase the risk of fractures in type 2 diabetes patients.
In 2014, Empagliflozin (drug of the gliflozin class) was approved for the treatment of type 2 diabetes in adults. It is a reversible, highly active, selective and competitive inhibitor of the sodium-dependent glucose transporter of type 2.
Sven Kohler, M.D., from Boehringer Ingelheim International in Germany, and researchers investigated the effect of Empagliflozin on bone fracture adverse events (AEs) and bone mineral density (BMD) in type 2 diabetes patients. They took data from a placebo-controlled trial (1:1:1; Empagliflozin 10 mg, Empagliflozin 25 mg, or placebo in phase I to III clinical trials) comprising more than 4,000 participants.
Bone fractures were diagnosed in 2.8% participants of 10 mg group, 2.5% in the 25 mg group of Empagliflozin and 2.9% in the placebo group. Fractures were noted in 4.1% and 4.2% of participants in a comparative study of Empagliflozin and Glimepiride. Thus no significant difference was found in fracture risk in any of the three groups showing that Empagliflozin is not associated with increasing the risk of fracture in type 2 diabetes patients.